Table 2.
Univariate analyses of factors associated with overall survival in hepatocellular carcinoma after hepatectomy
| Median survival (months)a | 5-year OS rate (%) | P value | |
|---|---|---|---|
|
Age (yr) |
|
|
|
| ≦60 |
28.96 ± 3.98 (21.165 to 36.755) |
40.4 |
0.338 |
| >60 |
15.02 ± 19.37 (0 to 52.977) |
34.6 |
|
|
Gender |
|
|
|
| Male |
22.68 ± 5.44 (12.020 to 33.340) |
30.1 |
0.068 |
| Female |
28.14 ± 6.45 (15.491 to 40.789) |
62.5 |
|
|
Alcohol |
|
|
|
| Yes |
19.40 ± 7.87 (3.968 to 34.832) |
18.5 |
0.027 |
| No |
47.08 ± 32.31 (0 to 110.413) |
46.6 |
|
|
Hepatitis B virus |
|
|
|
|
Positive |
28.96 ± 3.74 (21.630 to 36.290) |
40.3 |
0.332 |
|
Negative |
17.72 ± 3.66 (10.556 to 24.884) |
32.7 |
|
|
Hepatitis C virus |
|
|
|
| Positive |
47.08 ± 38.99 (0 to 123.488) |
41.7 |
0.665 |
| Negative |
28.14 ± 5.04 (18.265 to 38.015) |
37.2 |
|
|
Preoperativeα-fetoprotein (ng/ml) |
|
|
|
| ≦20 |
61.91 ± 31.65 (0 to 123.934) |
51.3 |
0.847 |
| >20 |
27.88 ± 6.69 (14.772 to 40.988) |
33.4 |
|
|
Child-Pugh classification |
|
|
|
| A |
28.96 ± 7.08 (15.086 to 42.834) |
38.7 |
0.461 |
| B |
19.40 ± 0 (−− to --) |
0 |
|
|
Size (cm) |
|
|
|
| ≦5 |
61.91 ± 34.99 (0 to 130.486) |
58.3 |
0.310 |
| >5 |
22.68 ± 5.46 (11.988 to 33.372) |
30.7 |
|
|
Encapsulation |
|
|
|
| Yes |
47.08 ± 28.79 (0 to 103.515) |
48.6 |
0.122 |
| No |
19.10 ± 3.34 (12.551 to 25.649) |
28.6 |
|
|
Tumor rupture |
|
|
|
| Yes |
27.88 ± 4.99 (18.105 to 37.655) |
32.9 |
0.206 |
| No |
80.55 ± 46.93 (0 to 172.539) |
75.0 |
|
|
Vascular invasion |
|
|
|
| Yes |
17.72 ± 4.26 (9.373 to 26.067) |
9.0 |
0.005 |
| No |
61.91 ± 31.46 (0.240 to 123.58) |
51.3 |
|
|
Daughter nodules |
|
|
|
| Yes |
17.72 ± 8.14 (1.760 to 33.680) |
10.8 |
|
| No |
47.08 ± 26.69 (0 to 98.611) |
48.6 |
0.009 |
|
Resection margin |
|
|
|
| Positive |
7.63 ± 2.17 (3.379 to 11.881) |
20.0 |
0.029 |
| Negative |
32.71 ± 9.00 (15.067 to 50.353) |
40.1 |
|
|
Liver cirrhosis |
|
|
|
| Positive |
28.96 ± 8.66 (11.981 to 45.939) |
41.0 |
0.791 |
| Negative |
22.68 ± 9.37 (4.322 to 41.038) |
33.3 |
|
|
Edmonson and Steiner grade |
|
|
|
| I |
36.91 ± 36.64 (0 to 133.736) |
60.0 |
0.063 |
| II |
80.55 ± 32.99 (15.895 to 145.205) |
60.0 |
|
| III |
22.68 ± 5.46 (11.978 to 33.382) |
24.2 |
|
| IV |
17.72 ± 3.20 (11.443 to 23.997) |
0 |
|
|
Stage |
|
|
|
| I |
101.98 ± 0 (−− to --) |
55.6 |
0.020 |
| II |
61.91 ± 22.30 (18.198 to 105.622) |
75.0 |
|
| III |
19.40 ± 3.33 (12.873 to 25.927) |
22.5 |
|
| IV |
11.34 ± 6.12 (0 to 23.326) |
0 |
|
|
CK19 liver b |
|
|
|
| Positive |
9.37 ± 3.28 (2.942 to 15.798) |
11.1 |
0.026 |
| Negative |
28.96 ± 20.96 (0 to 70.039) |
45.8 |
|
|
CK19 LN c |
|
|
|
| Positive |
9.37 ± 3.17 (3.165 to 15.575) |
0 |
0.007 |
| Negative | 28.96 ± 12.92 (3.642 to 54.278) | 43.3 |
aMedian survival±standard error (95% confidence interval).
bImmunohistochemical staining of primary liver tumor specimen for CK19.
c Immunohistochemical staining of lymph nodes specimen for CK19.